Peposertib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Peposertib comprises 9 peer-reviewed publications across 8 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Neoplasms, and Neuroendocrine Tumors. Most recent publication: Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial., Target Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
    Rubio-San-Simón A, Marshall LV, Karamouza E, et al. · Target Oncol · 2026
    PubMed: PMID 41838385 · NCT02813135 (ESMART) · Neoplasms
  2. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
    Pasqualini C, Rubino J, Brard C, et al. · Eur J Cancer · 2021
    PubMed: PMID 33892407 · NCT02813135 (ESMART) · Neoplasms
  3. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
    Morscher RJ, Brard C, Berlanga P, et al. · Eur J Cancer · 2021
    PubMed: PMID 34543871 · NCT02813135 (ESMART) · Neoplasms
  4. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
    Johnstone CN, Osellame LD, Cao Z, et al. · J Nucl Med · 2025
    PubMed: PMID 39884775 · NCT05868174
  5. hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.
    Chauhan A, Prieur A, Kolesar J, et al. · Cancers (Basel) · 2023
    PubMed: PMID 35205614 · NCT04750954 · Neuroendocrine Tumors
  6. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
    Berlanga P, Pierron G, Lacroix L, et al. · Cancer Discov · 2022
    PubMed: PMID 35292802 · NCT02813135 (ESMART) · Neoplasms
  7. Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension.
    Becker A, Krebs-Brown A, Vetter C, et al. · Clin Transl Sci · 2024
    PubMed: PMID 37905356 · NCT04702698
  8. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
    Bautista F, Paoletti X, Rubino J, et al. · J Clin Oncol · 2021
    PubMed: PMID 34347542 · NCT02813135 (ESMART) · Neoplasms

Publications by year

2020–2026: 9 publications.

2020
1
2021
3
2022
1
2023
1
2024
1
2025
1
2026
1

Publications by indication

Neoplasms (6)

  • Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
    Target Oncol · 2026 · PMID 41838385 · NCT02813135
  • The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
    Cancer Discov · 2022 · PMID 35292802 · NCT02813135
  • Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
    Eur J Cancer · 2021 · PMID 33892407 · NCT02813135
  • First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
    Eur J Cancer · 2021 · PMID 34543871 · NCT02813135
  • Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
    J Clin Oncol · 2021 · PMID 34347542 · NCT02813135

Neuroendocrine Tumors (1)

  • hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.
    Cancers (Basel) · 2023 · PMID 35205614 · NCT04750954

Publications by journal

All Peposertib publications (9)

2026 (1 paper)

  1. Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
    Rubio-San-Simón A, Marshall LV, Karamouza E, et al. · Target Oncol · 2026 · Derived
    PubMed: PMID 41838385 · NCT02813135 (ESMART) · Neoplasms

2025 (1 paper)

  1. DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
    Johnstone CN, Osellame LD, Cao Z, et al. · J Nucl Med · 2025 · Derived
    PubMed: PMID 39884775 · NCT05868174

2024 (1 paper)

  1. Phase I crossover study of DNA-protein kinase inhibitor peposertib in healthy volunteers: Effect of food and pharmacokinetics of an oral suspension.
    Becker A, Krebs-Brown A, Vetter C, et al. · Clin Transl Sci · 2024 · Derived
    PubMed: PMID 37905356 · NCT04702698

2023 (1 paper)

  1. hPG80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.
    Chauhan A, Prieur A, Kolesar J, et al. · Cancers (Basel) · 2023 · Derived
    PubMed: PMID 35205614 · NCT04750954 · Neuroendocrine Tumors

2022 (1 paper)

  1. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.
    Berlanga P, Pierron G, Lacroix L, et al. · Cancer Discov · 2022 · Derived
    PubMed: PMID 35292802 · NCT02813135 (ESMART) · Neoplasms

2021 (3 papers)

  1. Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium.
    Pasqualini C, Rubino J, Brard C, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33892407 · NCT02813135 (ESMART) · Neoplasms
  2. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
    Morscher RJ, Brard C, Berlanga P, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 34543871 · NCT02813135 (ESMART) · Neoplasms
  3. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
    Bautista F, Paoletti X, Rubino J, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34347542 · NCT02813135 (ESMART) · Neoplasms

2020 (1 paper)

  1. Sequential or combined designs for Phase I/II clinical trials? A simulation study.
    Rossoni C, Bardet A, Geoerger B, et al. · Clin Trials · 2020 · Derived
    PubMed: PMID 31538815 · NCT02813135 (ESMART) · Neoplasms

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).